In a significant move aimed at reducing out-of-pocket costs for millions of Americans, five popular diabetes medications are now included in the latest round of Medicare price cuts. This initiative, part of the Biden administration's efforts to lower prescription drug prices, will see substantial reductions in the cost of these essential treatments for Medicare beneficiaries.

The affected diabetes medications and their negotiated prices include:

1. Januvia (sitagliptin) – A DPP-4 inhibitor by Merck Sharp Dohme, now priced at $113 for a 30-day supply, reflecting a 79% reduction.
2. Fiasp (insulin aspart) – A fast-acting insulin from Novo Nordisk, with a new price of $119 for a 30-day supply, down by 76%.
3. NovoLog (insulin aspart) – Another fast-acting insulin by Novo Nordisk, also reduced to $119 for a 30-day supply, a 76% decrease.
4. Farxiga (dapagliflozin) – An SGLT2 inhibitor from AstraZeneca, now available at $178.50 for a 30-day supply, a 68% reduction.
5. Jardiance (empagliflozin) – An SGLT2 inhibitor co-manufactured by Boehringer Ingelheim and Eli Lilly, now priced at $197 for a 30-day supply, with a 66% reduction.

These price reductions are expected to make a significant impact on the affordability of diabetes care, potentially saving billions of dollars for Medicare and its beneficiaries.

For more details, visit PBS or Reuters.